{
    "nctId": "NCT01160718",
    "briefTitle": "Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy",
    "officialTitle": "Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) \u00bd Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Disease control (sum of complete response, partial response, and stable disease) at 24 weeks or more according to RECIST 1.1 criteria",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Not amenable to curative therapy\n* HER-2 positive disease allowed\n* Disease relapse or progression after aromatase inhibitor as adjuvant therapy or for advanced stage disease\n* Bilateral breast cancer allowed provided tumor endocrine sensitivity has been proven on both sides\n* Measurable disease according to RECIST criteria v1.1 or other lesions assessable by radiological exams (i.e., bone-only disease or small but unequivocal liver or lung metastases)\n* Received no more than 1 line of chemotherapy for advanced stage disease\n* Estrogen receptor- and/or progesterone receptor-positive (\u2265 10% tumor cells positive by immunohistochemistry or \u2265 10 fmol/mg cytosol protein by ligand binding assay)\n* No known CNS metastases\n\n  * Patients with brain metastases treated with radiotherapy and without any sign of brain progression after \u2265 3 months since the end of radiotherapy may be considered eligible after trial chair approval)\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0-2\n* Postmenopausal\n* Hemoglobin \u2265 90 g/L\n* Platelet count \u2265 100 x 10\\^9/L\n* Absolute neutrophil count \u2265 1.5 x 10\\^9/L\n* Creatinine clearance \u2265 30 mL/min\n* ALT \u2264 2.5 times upper limit of normal (ULN) (\u2264 5 times ULN in patients with liver metastases)\n* Bilirubin \u2264 1.5 times ULN\n* INR \\< 1.6\n* PTT normal\n* LVEF \u2265 50%\n* Able to swallow AZD6244/placebo capsules\n* Capable of understanding information given by the investigator on the trial\n* Must adhere to and be geographically proximal to allow for proper staging, treatment, and follow up\n* No contraindication for intramuscular injections\n* No bleeding diathesis\n* No current or prior malignancy other than breast cancer within the past 5 years, except carcinoma in situ of the cervix or basal cell carcinoma of the skin treated curatively\n* No serious underlying medical condition that, in the judgment of the investigator, would impair the ability of the patient to participate in the trial (e.g., active autoimmune disease or uncontrolled diabetes)\n* No refractory nausea and vomiting, chronic gastrointestinal disease (e.g., inflammatory bowel disease), or significant bowel resection that preclude adequate absorption\n* No psychiatric disorder precluding understanding of information on trial-related topics, giving informed consent, or interfering with adherence for oral drug intake\n* No uncontrolled hypertension (systolic BP \\> 150 mm Hg and/or diastolic BP \\> 100 mm Hg, measured repeatedly at more than two visits despite adequate treatment with at least two different antihypertensive drugs)\n* No clinically significant (i.e., active) cardiovascular disease, including any of the following:\n\n  * Cerebrovascular accident/stroke or myocardial infarction within the past 6 months\n  * Unstable angina\n  * NYHA class III-IV congestive heart failure\n  * Serious cardiac arrhythmia or AV-block \\> 1, requiring medication during the trial and which might interfere with regularity of the trial treatment, or not controlled by medication\n* No known hypersensitivity to trial drugs or any other component of the trial drugs\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* At least 30 days since other prior experimental drugs or participation in another clinical trial\n* No prior fulvestrant, AZD6244, MEK inhibitors, RAF inhibitors, or endocrine therapies other than aromatase inhibitors (e.g., anastrazole, letrozole, or exemestane) or tamoxifen\n* No more than 1 line of aromatase inhibitors (steroidal and nonsteroidal aromatase inhibitors are considered two different lines)\n* No concurrent full-dose anticoagulation therapy (e.g., low molecular weight heparin, acenocoumarol, phenprocoumon, or analogues)\n\n  * Prophylactic doses of anticoagulation or antiplatelet may be allowed\n* No concurrent radiotherapy\n* No other concurrent anticancer therapy or experimental drugs\n* Concurrent bisphosphonate allowed provided the investigator rules out tumor progression",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}